GapNYSE: GPS

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on October 28, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Global Market.

The Gap, Inc.'s Q3 report is important as the company needs to show continued progress in the recently successful brand turnaround. A weak consumer weighs on the Q3 outlook, causing a more moderate growth outlook, but GAP should still report good comparable results due to the good brand momentum. As the market has remained skeptical of GAP's turnaround despite the recent successful quarters, the stock now brings an attractive risk-to-reward.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

I reiterate my hold rating for Moody's due to its valuation premium compared to S&P Global, despite strong fundamentals. MCO's 3Q24 earnings report showed impressive revenue and EPS growth, driven by strong performance in Moody's Investor Services (MIS) segment. The valuation gap between MCO and SPGI is closing, suggesting a more favorable entry point for patient investors may soon emerge.

GAP is well-positioned for long-term growth, supported by its strategic focus on improving brands and maintaining financial and operational rigor.

NextNav's Next-Generation 3D Terrestrial PNT Solution in Lower 900 MHz Band has Potential to Save US Economy $663 Million for One Day of a Global GPS Outage NextNav's Next-Generation 3D Terrestrial PNT Solution in Lower 900 MHz Band has Potential to Save US Economy $663 Million for One Day of a Global GPS Outage

Note: Gap's FY'23 ended on February 3, 2024.

WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week's $1b+ revenue potential announcement.